Gas plasma irradiation of breast cancers promotes immunogenicity, tumor reduction, and an abscopal effect in vivo.
ICD
immunogenic cancer cell death
leukocytes
medical technology
oncology
plasma medicine
reactive oxygen species
ros
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
29 12 2020
29 12 2020
Historique:
entrez:
18
1
2021
pubmed:
19
1
2021
medline:
29
7
2021
Statut:
epublish
Résumé
While many new and emerging therapeutic concepts have appeared throughout the last decades, cancer still is fatal in many patients. At the same time, the importance of immunology in oncotherapy is increasingly recognized, not only since the advent of checkpoint therapy. Among the many types of tumors, also breast cancer has an immunological dimension that might be exploited best by increasing the immunogenicity of the tumors in the microenvironment. To this end, we tested a novel therapeutic concept, gas plasma irradiation, for its ability to promote the immunogenicity and increase the toxicity of breast cancer cells in vitro and in vivo. Mechanistically, this emerging medical technology is employing a plethora of reactive oxygen species being deposited on the target cells and tissues. Using 2D cultures and 3D tumor spheroids, we found gas plasma-irradiation to drive apoptosis and immunogenic cancer cell death (ICD) in vitro, as evidenced by an increased expression of calreticulin, heat-shock proteins 70 and 90, and MHC-I. In 4T1 breast cancer-bearing mice, the gas plasma irradiation markedly decreased tumor burden and increased survival. Interestingly, non-treated tumors injected in the opposite flank of mice exposed to our novel treatment also exhibited reduced growth, arguing for an abscopal effect. This was concomitant with an increase of apoptosis and tumor-infiltrating CD4
Identifiants
pubmed: 33457077
doi: 10.1080/2162402X.2020.1859731
pii: 1859731
pmc: PMC7781742
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1859731Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
Clin Cancer Res. 2013 Sep 1;19(17):4801-15
pubmed: 23838316
Strahlenther Onkol. 2018 Jun;194(6):509-519
pubmed: 29500551
J Vis Exp. 2017 Nov 17;(129):
pubmed: 29286412
Environ Mol Mutagen. 2018 May;59(4):268-277
pubmed: 29417643
Sci Rep. 2017 Jun 5;7(1):2791
pubmed: 28584285
Oncoimmunology. 2017 Aug 9;6(11):e1356148
pubmed: 29147608
Cancer Res. 2010 Nov 1;70(21):8368-77
pubmed: 20940398
Int J Mol Sci. 2017 Apr 19;18(4):
pubmed: 28422070
Trends Biotechnol. 2018 Nov;36(11):1183-1198
pubmed: 30033340
Nat Med. 2007 Jan;13(1):54-61
pubmed: 17187072
Biomed Res Int. 2013;2013:482160
pubmed: 23509727
Salud Publica Mex. 2011 Sep-Oct;53(5):372-84
pubmed: 22218791
Oncotarget. 2017 May 30;8(22):35482-35483
pubmed: 28415657
Nat Rev Cancer. 2012 Mar 22;12(4):237-51
pubmed: 22437869
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643231
J Cancer Sci Ther. 2009 Dec 1;1(2):1-4
pubmed: 20740081
Mutat Res Genet Toxicol Environ Mutagen. 2016 Mar;798-799:48-54
pubmed: 26994493
J Immunol. 2015 Mar 1;194(5):2049-56
pubmed: 25710958
Sci Rep. 2019 Mar 11;9(1):4099
pubmed: 30858524
Nat Rev Cancer. 2003 May;3(5):380-7
pubmed: 12724736
Oncotarget. 2016 Jul 26;7(30):47242-47251
pubmed: 27363018
Cell Physiol Biochem. 2015;37(4):1560-71
pubmed: 26513143
Redox Biol. 2020 Feb;30:101423
pubmed: 31931281
Chem Sci. 2016 Jan 1;7(1):489-498
pubmed: 28791102
Cancer Gene Ther. 2020 May 27;:
pubmed: 32457487
Adv Cancer Res. 2014;122:1-67
pubmed: 24974178
Br J Radiol. 1953 May;26(305):234-41
pubmed: 13042090
Sci Rep. 2018 May 16;8(1):7689
pubmed: 29769707
Sci Rep. 2019 Mar 11;9(1):4112
pubmed: 30858416
Science. 2020 Jan 31;367(6477):
pubmed: 32001626
Immunol Rev. 2017 Nov;280(1):126-148
pubmed: 29027218
Exp Mol Med. 2020 Feb;52(2):192-203
pubmed: 32060354
Oxid Med Cell Longev. 2010 Jan-Feb;3(1):23-34
pubmed: 20716925
Semin Radiat Oncol. 2015 Jan;25(1):11-7
pubmed: 25481261
Front Immunol. 2018 Jan 22;9:14
pubmed: 29403496
Cancers (Basel). 2020 Sep 09;12(9):
pubmed: 32917026
PLoS One. 2016 Sep 01;11(9):e0160667
pubmed: 27584003
Cancer Res. 2013 Jan 1;73(1):19-29
pubmed: 23087058
Ecancermedicalscience. 2012 Nov 14;6:ed16
pubmed: 24883085
J Leukoc Biol. 2009 Sep;86(3):549-55
pubmed: 19564570
Sci Rep. 2020 Jan 20;10(1):686
pubmed: 31959787
Sci Rep. 2016 Jan 25;6:19740
pubmed: 26804478
PLoS One. 2012;7(3):e31732
pubmed: 22412839
Oncoimmunology. 2014 Apr 25;3:e28518
pubmed: 25071979
Lancet Oncol. 2020 Jan;21(1):44-59
pubmed: 31786121
PLoS One. 2013 Sep 11;8(9):e73741
pubmed: 24040051
Oncotarget. 2019 Jan 15;10(5):573-583
pubmed: 30728908
Nat Rev Immunol. 2017 Feb;17(2):97-111
pubmed: 27748397
Curr Probl Cancer. 2016 Jan-Feb;40(1):10-24
pubmed: 26612692
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Acta Pharm Sin B. 2015 Sep;5(5):402-18
pubmed: 26579471
Int J Mol Sci. 2020 Feb 18;21(4):
pubmed: 32085661
J Leukoc Biol. 2016 Oct;100(4):791-799
pubmed: 26992432
Clin Cancer Res. 2006 Jan 15;12(2):465-72
pubmed: 16428488
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
Ecancermedicalscience. 2019;13:961
pubmed: 31537986
Nat Immunol. 2013 Mar;14(3):281-9
pubmed: 23334788
Sci Rep. 2017 Nov 28;7(1):16478
pubmed: 29184131
Oncoimmunology. 2018 Jul 26;7(9):e1484978
pubmed: 30228954
Nature. 2018 Oct;562(7725):20-21
pubmed: 30279600
Cancers (Basel). 2019 Sep 01;11(9):
pubmed: 31480642
Oxid Med Cell Longev. 2019 Oct 8;2019:9062098
pubmed: 31687089
Nat Rev Cancer. 2012 Dec;12(12):860-75
pubmed: 23151605
Trends Immunol. 2007 Oct;28(10):429-36
pubmed: 17845865
Cancer Treat Rev. 2010 Dec;36(8):615-20
pubmed: 20478658
Sci Rep. 2016 Jul 07;6:29048
pubmed: 27383714
Free Radic Biol Med. 2018 Aug 20;124:205-213
pubmed: 29870749
Oxid Med Cell Longev. 2017;2017:4396467
pubmed: 28761621
JAMA Oncol. 2019 Jul 1;5(7):1043-1047
pubmed: 31021392
Oncotarget. 2016 Jul 5;7(27):41622-41636
pubmed: 27223435
Cancers (Basel). 2020 Jan 22;12(2):
pubmed: 31979114
Surgery. 2020 Mar;167(3):628-630
pubmed: 31623855
Semin Cancer Biol. 2013 Oct;23(5):380-90
pubmed: 23994764
Front Pharmacol. 2018 Nov 13;9:1300
pubmed: 30483135
Free Radic Res. 2014 May;48(5):542-9
pubmed: 24528134
Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):212-224
pubmed: 32417411
Clin Cancer Res. 2008 Feb 15;14(4):1159-66
pubmed: 18281550
Breast Cancer Res Treat. 2016 Apr;156(2):237-47
pubmed: 26960711
Antioxid Redox Signal. 2014 Mar 1;20(7):1086-97
pubmed: 23373831
Cancer Res. 2011 Jul 15;71(14):4821-33
pubmed: 21602432
Br J Radiol. 1973 Mar;46(543):220-2
pubmed: 4706791
Science. 2015 Apr 3;348(6230):69-74
pubmed: 25838375
Curr Breast Cancer Rep. 2017;9(1):45-51
pubmed: 28344743
Methods Mol Biol. 2019;1904:83-108
pubmed: 30539467
Adv Sci (Weinh). 2020 Mar 30;7(10):1903438
pubmed: 32440479
Sci Rep. 2019 Jan 24;9(1):634
pubmed: 30679720
Oncotarget. 2017 Jun 8;8(37):62742-62758
pubmed: 28977985
Clin Cancer Res. 2020 Jun 15;26(12):2777-2782
pubmed: 32047000
Biofactors. 2013 Jul-Aug;39(4):355-67
pubmed: 23900966
Int J Cancer. 2014 Sep 1;135(5):1165-77
pubmed: 24500981
Int J Mol Sci. 2017 May 03;18(5):
pubmed: 28467380
Lancet Oncol. 2020 Jan;21(1):3-5
pubmed: 31786122
Nat Genet. 2019 Feb;51(2):202-206
pubmed: 30643254
Curr Med Chem. 2012;19(12):1751-64
pubmed: 22414083
J Immunol. 2005 Mar 1;174(5):2591-601
pubmed: 15728465
J Hematol Oncol. 2019 Dec 21;12(1):140
pubmed: 31864424
Cancer Immunol Res. 2015 Jun;3(6):610-9
pubmed: 25701325
Adv Sci (Weinh). 2019 Jan 28;6(6):1802062
pubmed: 30937272